195 related articles for article (PubMed ID: 36401040)
1. Exon-Skipping for a Pathogenic COL6A1 Variant in Ullrich Congenital Muscular Dystrophy.
Aguti S; Guirguis F; Bönnemann C; Muntoni F; Bolduc V; Zhou H
Methods Mol Biol; 2023; 2587():387-407. PubMed ID: 36401040
[TBL] [Abstract][Full Text] [Related]
2. Designing Effective Antisense Oligonucleotides for Exon Skipping.
Shimo T; Maruyama R; Yokota T
Methods Mol Biol; 2018; 1687():143-155. PubMed ID: 29067661
[TBL] [Abstract][Full Text] [Related]
3. Exon-Skipping Oligonucleotides Restore Functional Collagen VI by Correcting a Common COL6A1 Mutation in Ullrich CMD.
Aguti S; Bolduc V; Ala P; Turmaine M; Bönnemann CG; Muntoni F; Zhou H
Mol Ther Nucleic Acids; 2020 Sep; 21():205-216. PubMed ID: 32585628
[TBL] [Abstract][Full Text] [Related]
4. Tips to Design Effective Splice-Switching Antisense Oligonucleotides for Exon Skipping and Exon Inclusion.
Maruyama R; Yokota T
Methods Mol Biol; 2018; 1828():79-90. PubMed ID: 30171536
[TBL] [Abstract][Full Text] [Related]
5. Identification and characterization of novel collagen VI non-canonical splicing mutations causing Ullrich congenital muscular dystrophy.
Martoni E; Urciuolo A; Sabatelli P; Fabris M; Bovolenta M; Neri M; Grumati P; D'Amico A; Pane M; Mercuri E; Bertini E; Merlini L; Bonaldo P; Ferlini A; Gualandi F
Hum Mutat; 2009 May; 30(5):E662-72. PubMed ID: 19309692
[TBL] [Abstract][Full Text] [Related]
6. Recent advancements in exon-skipping therapies using antisense oligonucleotides and genome editing for the treatment of various muscular dystrophies.
Hwang J; Yokota T
Expert Rev Mol Med; 2019 Oct; 21():e5. PubMed ID: 31576784
[TBL] [Abstract][Full Text] [Related]
7. The recurrent deep intronic pseudoexon-inducing variant
Foley AR; Bolduc V; Guirguis F; Donkervoort S; Hu Y; Orbach R; McCarty RM; Sarathy A; Norato G; Cummings BB; Lek M; Sarkozy A; Butterfield RJ; Kirschner J; Nascimento A; Benito DN; Quijano-Roy S; Stojkovic T; Merlini L; Comi G; Ryan M; McDonald D; Munot P; Yoon G; Leung E; Finanger E; Leach ME; Collins J; Tian C; Mohassel P; Neuhaus SB; Saade D; Cocanougher BT; Chu ML; Scavina M; Grosmann C; Richardson R; Kossak BD; Gospe SM; Bhise V; Taurina G; Lace B; Troncoso M; Shohat M; Shalata A; Chan SHS; Jokela M; Palmio J; Haliloğlu G; Jou C; Gartioux C; Solomon-Degefa H; Freiburg CD; Schiavinato A; Zhou H; Aguti S; Nevo Y; Nishino I; Jimenez-Mallebrera C; Lamandé SR; Allamand V; Gualandi F; Ferlini A; MacArthur DG; Wilton SD; Wagener R; Bertini E; Muntoni F; Bönnemann CG
medRxiv; 2024 Mar; ():. PubMed ID: 38585825
[TBL] [Abstract][Full Text] [Related]
8. New developments in exon skipping and splice modulation therapies for neuromuscular diseases.
Touznik A; Lee JJ; Yokota T
Expert Opin Biol Ther; 2014 Jun; 14(6):809-19. PubMed ID: 24620745
[TBL] [Abstract][Full Text] [Related]
9. Molecular correction of Duchenne muscular dystrophy by splice modulation and gene editing.
Hanson B; Wood MJA; Roberts TC
RNA Biol; 2021 Jul; 18(7):1048-1062. PubMed ID: 33472516
[TBL] [Abstract][Full Text] [Related]
10. In vitro evaluation of novel antisense oligonucleotides is predictive of in vivo exon skipping activity for Duchenne muscular dystrophy.
Wang Q; Yin H; Camelliti P; Betts C; Moulton H; Lee H; Saleh AF; Gait MJ; Wood MJ
J Gene Med; 2010 Apr; 12(4):354-64. PubMed ID: 20235089
[TBL] [Abstract][Full Text] [Related]
11. Homozygous splice variant (c.1741-6G>A) of the COL6A1 gene in three patients with Ullrich congenital muscular dystrophy.
Barington M; Dunø M; Birkedal U; Vissing J; Born AP; Krag T; Hansen TVO; Østergaard E
Neuromuscul Disord; 2023 Jul; 33(7):539-545. PubMed ID: 37315421
[TBL] [Abstract][Full Text] [Related]
12. In Vivo Evaluation of Single-Exon and Multiexon Skipping in mdx52 Mice.
Mizobe Y; Miyatake S; Takizawa H; Hara Y; Yokota T; Nakamura A; Takeda S; Aoki Y
Methods Mol Biol; 2018; 1828():275-292. PubMed ID: 30171548
[TBL] [Abstract][Full Text] [Related]
13. A recurrent COL6A1 pseudoexon insertion causes muscular dystrophy and is effectively targeted by splice-correction therapies.
Bolduc V; Foley AR; Solomon-Degefa H; Sarathy A; Donkervoort S; Hu Y; Chen GS; Sizov K; Nalls M; Zhou H; Aguti S; Cummings BB; Lek M; Tukiainen T; Marshall JL; Regev O; Marek-Yagel D; Sarkozy A; Butterfield RJ; Jou C; Jimenez-Mallebrera C; Li Y; Gartioux C; Mamchaoui K; Allamand V; Gualandi F; Ferlini A; Hanssen E; ; Wilton SD; Lamandé SR; MacArthur DG; Wagener R; Muntoni F; Bönnemann CG
JCI Insight; 2019 Mar; 4(6):. PubMed ID: 30895940
[TBL] [Abstract][Full Text] [Related]
14. Digital Droplet PCR for the Absolute Quantification of Exon Skipping Induced by Antisense Oligonucleotides in (Pre-)Clinical Development for Duchenne Muscular Dystrophy.
Verheul RC; van Deutekom JC; Datson NA
PLoS One; 2016; 11(9):e0162467. PubMed ID: 27612288
[TBL] [Abstract][Full Text] [Related]
15. Precision Medicine through Antisense Oligonucleotide-Mediated Exon Skipping.
Li D; Mastaglia FL; Fletcher S; Wilton SD
Trends Pharmacol Sci; 2018 Nov; 39(11):982-994. PubMed ID: 30282590
[TBL] [Abstract][Full Text] [Related]
16. Antisense oligonucleotide induced pseudoexon skipping and restoration of functional protein for Fukuyama muscular dystrophy caused by a deep-intronic variant.
Enkhjargal S; Sugahara K; Khaledian B; Nagasaka M; Inagaki H; Kurahashi H; Koshimizu H; Toda T; Taniguchi-Ikeda M
Hum Mol Genet; 2023 Apr; 32(8):1301-1312. PubMed ID: 36426838
[TBL] [Abstract][Full Text] [Related]
17. In silico screening based on predictive algorithms as a design tool for exon skipping oligonucleotides in Duchenne muscular dystrophy.
Echigoya Y; Mouly V; Garcia L; Yokota T; Duddy W
PLoS One; 2015; 10(3):e0120058. PubMed ID: 25816009
[TBL] [Abstract][Full Text] [Related]
18. Systemic administration of the antisense oligonucleotide NS-065/NCNP-01 for skipping of exon 53 in patients with Duchenne muscular dystrophy.
Komaki H; Nagata T; Saito T; Masuda S; Takeshita E; Sasaki M; Tachimori H; Nakamura H; Aoki Y; Takeda S
Sci Transl Med; 2018 Apr; 10(437):. PubMed ID: 29669851
[TBL] [Abstract][Full Text] [Related]
19. In Vitro Multiexon Skipping by Antisense PMOs in Dystrophic Dog and Exon 7-Deleted DMD Patient.
Nakamura A; Aoki Y; Tsoumpra M; Yokota T; Takeda S
Methods Mol Biol; 2018; 1828():151-163. PubMed ID: 30171540
[TBL] [Abstract][Full Text] [Related]
20. Exonic sequences provide better targets for antisense oligonucleotides than splice site sequences in the modulation of Duchenne muscular dystrophy splicing.
Aartsma-Rus A; Houlleberghs H; van Deutekom JC; van Ommen GJ; 't Hoen PA
Oligonucleotides; 2010 Apr; 20(2):69-77. PubMed ID: 20377429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
